Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of "Buy" by Brokerages

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) has earned an average rating of "Buy" from the seven research firms that are currently covering the company, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have covered the stock in the last year is $12.33.

Separately, HC Wainwright reissued a "buy" rating and set a $13.00 price target on shares of Tango Therapeutics in a research note on Monday, April 14th.

Institutional Investors Weigh In On Tango Therapeutics

Several institutional investors have recently added to or reduced their stakes in TNGX. Dynamic Technology Lab Private Ltd bought a new position in Tango Therapeutics in the 4th quarter worth about $33,000. Stonebrook Private Inc. bought a new position in shares of Tango Therapeutics in the fourth quarter worth $34,000. Ameriprise Financial Inc. bought a new stake in Tango Therapeutics during the fourth quarter valued at $35,000. Sherbrooke Park Advisers LLC purchased a new position in Tango Therapeutics during the fourth quarter worth about $38,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Tango Therapeutics during the 4th quarter valued at about $40,000. 78.99% of the stock is owned by hedge funds and other institutional investors.

Tango Therapeutics Trading Up 1.8 %

TNGX stock traded up $0.02 during trading hours on Friday, hitting $1.12. 467,242 shares of the stock were exchanged, compared to its average volume of 1,079,341. The company has a 50-day simple moving average of $1.51 and a two-hundred day simple moving average of $2.69. The firm has a market capitalization of $121.08 million, a P/E ratio of -0.95 and a beta of 1.02. Tango Therapeutics has a 12 month low of $1.03 and a 12 month high of $12.02.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). The company had revenue of $4.12 million for the quarter, compared to the consensus estimate of $7.84 million. Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. On average, equities research analysts predict that Tango Therapeutics will post -1.19 earnings per share for the current year.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.